Expression of Nociceptive Ligands in Canine Osteosarcoma

被引:13
|
作者
Shor, S. [1 ]
Fadl-Alla, B. A. [1 ]
Pondenis, H. C. [1 ]
Zhang, X. [2 ]
Wycislo, K. L. [2 ]
Lezmi, S. [2 ]
Fan, T. M. [1 ]
机构
[1] Univ Illinois, Dept Vet Clin Med, Urbana, IL 61802 USA
[2] Univ Illinois, Dept Pathobiol, Urbana, IL 61802 USA
关键词
Nociception; Osteoblast cytokines; Painful malignant osteolysis; TRANSITIONAL-CELL CARCINOMA; URINARY-BLADDER; CLINICAL-TRIAL; URETHRAL TUMORS; DOGS; PIROXICAM; CISPLATIN; MODEL; COMBINATION; MANAGEMENT;
D O I
10.1111/jvim.12511
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Background: Canine osteosarcoma ( OS) is associated with localized pain as a result of tissue injury from tumor infiltration and peritumoral inflammation. Malignant bone pain is caused by stimulation of peripheral pain receptors, termed nociceptors, which reside in the localized tumor microenvironment, including the periosteal and intramedullary bone cavities. Several nociceptive ligands have been determined to participate directly or indirectly in generating bone pain associated with diverse skeletal abnormalities. Hypothesis: Canine OS cells actively produce nociceptive ligands with the capacity to directly or indirectly activate peripheral pain receptors residing in the bone tumor microenvironment. Animals: Ten dogs with appendicular OS. Methods: Expression of nerve growth factor, endothelin- 1, and microsomal prostaglandin E synthase- 1 was characterized in OS cell lines and naturally occurring OS samples. In 10 dogs with OS, circulating concentrations of nociceptive ligands were quantified and correlated with subjective pain scores and tumor volume in patients treated with standardized palliative therapies. Results: Canine OS cells express and secrete nerve growth factor, endothelin- 1, and prostaglandin E2. Naturally occurring OS samples uniformly express nociceptive ligands. In a subset of OS- bearing dogs, circulating nociceptive ligand concentrations were detectable but failed to correlate with pain status. Localized foci of nerve terminal proliferation were identified in a minority of primary bone tumor samples. Conclusions and Clinical Importance: Canine OS cells express nociceptive ligands, potentially permitting active participation of OS cells in the generation of malignant bone pain. Specific inhibitors of nociceptive ligand signaling pathways might improve pain control in dogs with OS.
引用
收藏
页码:268 / 275
页数:8
相关论文
共 50 条
  • [31] Expression of Hepatocyte Growth Factor and the Proto-oncogenic Receptor c-Met in Canine Osteosarcoma
    Fieten, H.
    Spee, B.
    Ijzer, J.
    Kik, M. J.
    Penning, L. C.
    Kirpensteijn, J.
    VETERINARY PATHOLOGY, 2009, 46 (05) : 869 - 877
  • [32] Epidermal growth factor receptor expression in canine transitional cell carcinoma
    Hanazon, Kiwamu
    Fukumoto, Shinya
    Kawamura, Yoshio
    Endo, Yoshifumi
    Kadosawa, Tsuyoshi
    Iwano, Hidetomo
    Uchide, Tsuyoshi
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2015, 77 (01) : 1 - 6
  • [33] Association of Canine Osteosarcoma and Monocyte Phenotype and Chemotactic Function
    Tuohy, J. L.
    Lascelles, B. D. X.
    Griffith, E. H.
    Fogle, J. E.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2016, 30 (04) : 1167 - 1178
  • [34] Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma
    Withers, Sita S.
    Skorupski, Katherine A.
    York, Daniel
    Choi, Jin W.
    Woolard, Kevin D.
    Laufer-Amorim, Renee
    Sparger, Ellen E.
    Rodriguez, Carlos O.
    McSorley, Stephen J.
    Monjazeb, Arta M.
    Murphy, William J.
    Canter, Robert J.
    Rebhun, Robert B.
    VETERINARY AND COMPARATIVE ONCOLOGY, 2019, 17 (01) : 49 - 60
  • [35] Characterization of IGF2R Molecular Expression in Canine Osteosarcoma as Part of a Novel Comparative Oncology Approach
    Boisclair, Charles
    Dickinson, Ryan
    Giri, Sabeena
    Dadachova, Ekaterina
    MacDonald-Dickinson, Valerie
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [36] Adjuvant therapy with carboplatin and pamidronate for canine appendicular osteosarcoma
    Kozicki, A. R.
    Robat, C.
    Chun, R.
    Kurzman, I. D.
    VETERINARY AND COMPARATIVE ONCOLOGY, 2015, 13 (03) : 229 - 236
  • [37] Mechanical properties of canine osteosarcoma-affected antebrachia
    Steffey, Michele A.
    Garcia, Tanya C.
    Daniel, Leticia
    Zwingenberger, Allison L.
    Stover, Susan M.
    VETERINARY SURGERY, 2017, 46 (04) : 539 - 548
  • [38] Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma
    Laver, T.
    London, C. A.
    Vail, D. M.
    Biller, B. J.
    Coy, J.
    Thamm, D. H.
    VETERINARY AND COMPARATIVE ONCOLOGY, 2018, 16 (01) : E23 - E29
  • [39] Overexpression of the sis oncogene in a canine osteosarcoma cell line
    Levine, RA
    VETERINARY PATHOLOGY, 2002, 39 (03) : 411 - 412
  • [40] Recent and current clinical trials in canine appendicular osteosarcoma
    Poon, Andrew C.
    Matsuyama, Arata
    Mutsaers, Anthony J.
    CANADIAN VETERINARY JOURNAL-REVUE VETERINAIRE CANADIENNE, 2020, 61 (03): : 301 - 308